MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ACAD had $4,359K increase in cash & cash equivalents over the period. $73,900K in free cash flow.

Cash Flow Overview

Change in Cash
$4,359K
Free Cash flow
$73,900K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net income
71,779 45,653
Stock-based compensation
13,180 25,720
Amortization of premiums and accretion of discounts on investment securities
1,102 3,652
Amortization of intangible assets
2,723 5,444
Depreciation
227 442
Accounts receivable, net
8,345 8,766
Interest and other receivables
11,401 6,225
Inventory
-1,248 14,553
Prepaid expenses
8,121 -2,934
Other assets
700 1,306
Operating lease right-of-use assets
-2,212 -4,259
Accounts payable
1,650 3,905
Accrued liabilities
27,776 21,350
Operating lease liabilities
-2,179 -1,418
Long-term liabilities
-14,659 10,492
Net cash provided by operating activities
74,288 84,279
Purchases of investment securities
204,553 330,398
Sale and maturity of investment securities
125,589 262,190
Intangible assets
0 98,838
Purchases of property and equipment
388 297
Net cash used in investing activities
-79,352 -167,343
Proceeds from issuance of common stock, net of issuance costs
9,423 17,794
Net cash provided by financing activities
9,423 17,794
Effect of exchange rate changes on cash
0 19
Net decrease in cash, cash equivalents and restricted cash
4,359 -65,251
Cash and cash equivalents at beginning of period
328,359 -
Cash and cash equivalents at end of period
267,467 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

ACADIA PHARMACEUTICALS INC (ACAD)

ACADIA PHARMACEUTICALS INC (ACAD)